Osteoporosis: A Perspective for 2024
May 16, 2024
Virtual via Zoom
Strong bones are essential to health and quality of life. Osteoporosis and fragility fractures are common and can be debilitating but there are steps we can take to help reduce the risk. Because osteoporosis is asymptomatic until the first clinical fracture, many women do not realize they are at risk. This lecture will summarize the current approach to assessing bone health, as well as preventing and treating osteoporosis with a focus on postmenopausal women.
- Walker et al. Postmenopausal Osteoporosis. NEJM 2023; 389: 1979-1991 https://www.nejm.org/doi/full/10.1056/NEJMcp2307353
- LeBoff et al. Clinician’s guide to prevention and treatment of osteoporosis. OI 2022; 33(10):2049-2102 https://pubmed.ncbi.nlm.nih.gov/35478046/
- Eastell et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. JCEM 2019; May 1;104(5):1595-1622 https://pubmed.ncbi.nlm.nih.gov/30907953/
- Camacho et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY; Endocrine Practice 2020; 2020 May;26(5):564-570 https://pubmed.ncbi.nlm.nih.gov/32427525/
- Ensrud et al. Osteoporosis 2024. Annals of Internal Medicine Jan;177(1):ITC1-ITC16. doi: 10.7326/AITC202401160 https://pubmed.ncbi.nlm.nih.gov/38190715/
- Identify the causes and consequences of osteoporosis and quantify the burden of disease.
- Discuss strategies used to assess fracture risk and to diagnose osteoporosis.
- Describe the options for the prevention and treatment of osteoporosis.
- Define and explain the osteoporosis care gap.
This activity is intended for physicians, pharmacists, nurses, and all other interested stakeholders.
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.
Day 1 May 16, 2024
Time | Topic | Speaker |
---|---|---|
12:00 - 1:00 PM EDT | Osteoporosis: A Perspective for 2024 | Marcella Walker, MD |
![Jointly Accredited Provider](https://ceportal.fda.gov//files/content/docs/logo-joint-accreditation-provider.png)
![ICPE Credit](https://ceportal.fda.gov//files/content/docs/icpeCreditLogo.png)
All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.
Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor. If you do not see your credit reflected on CPE Monitor* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov. *CPE Monitor sets a strict 60-day limit on uploading credits.
Faculty
- Walker, Marcella, MD, Professor of Medicine, Columbia University - I have the following relationship(s): Alexion - Advisory Board; Amgen - research grant
Planning Committee
- Bersoff-Matcha, Susan, MD, Deputy Director, OC - nothing to disclose
- Shahidzadeh, Rokhsareh, RN, MSN, Senior Regulatory Health Education Specialist, FDA - nothing to disclose
- South, Erin, PharmD, Pharmacist, FDA - nothing to disclose
CE Consultation and Accreditation Team
- Harrison, Catherine, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
- Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
All relevant financial relationships have been mitigated.
Must attend 100% of the activity.